Figure 2.
EGFRapt-3WJ-siKRASG12C pRNA nanoparticles target EGFR-expressing cells and suppress KRAS expression in human lung cancer
(A and B) Cellular uptake of AF647-labeled pRNA nanoparticles after 1 h incubation was determined by flow cytometry assay. (C) KRAS mRNA expression was quantified by qRT-PCR assay 48 h post-treatment with pRNA nanoparticles. (D) KRAS protein expression and activation status of KRAS downstream pathway intermediates was assessed by immunoblotting assay 48 h post-treatment with pRNA nanoparticles. Error bars represent SD. Significance was calculated using Student’s t test: ∗∗p < 0.001.